transporter hOCT1 and their functional consequences. Pharmacogenetics 2002; 12(8):591–595.29 [29] Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Deyoung J, Carlson E, Ferrin TE, Herskowitz I, Giacomini KM, Investigators POMT. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A 2003; 100(10):5902–5907.
30 [30] Arimany‐Nardi C, Koepsell H, Pastor‐Anglada M. Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug‐drug interactions. Pharmacogenomics J 2015; 15(6):473–487.
31 [31] Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T, Abedian S, Cheon JH, Cho J, Dayani NE, Franke L, Fuyuno Y, Hart A, Juyal RC, Juyal G, Kim WH, Morris AP, Poustchi H, Newman WG, Midha V, Orchard TR, Vahedi H, Sood A, Sung JY, Malekzadeh R, Westra HJ, Yamazaki K, Yang SK, Barrett JC, Alizadeh BZ, Parkes M, Bk T, Daly MJ, Kubo M, Anderson CA, Weersma RK, Consortium IMSG, Consortium IIG. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 2015; 47(9):979–986.
32 [32] Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117(5):1422–1431.
33 [33] Chen L, Takizawa M, Chen E, Schlessinger A, Segenthelar J, Choi JH, Sali A, Kubo M, Nakamura S, Iwamoto Y, Iwasaki N, Giacomini KM. Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J Pharmacol Exp Ther 2010; 335(1):42–50.
34 [34] Yee SW, Brackman DJ, Ennis EA, Sugiyama Y, Kamdem LK, Blanchard R, Galetin A, Zhang L, Giacomini KM. Influence of transporter polymorphisms on drug disposition and response: a perspective from the international transporter consortium. Clin Pharmacol Ther 2018; 104(5):803–817.
35 [35] Tzvetkov MV, Saadatmand AR, Bokelmann K, Meineke I, Kaiser R, Brockmöller J. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5‐HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J 2012; 12(1):22–29.
36 [36] Liang X, Yee SW, Chien HC, Chen EC, Luo Q, Zou L, Piao M, Mifune A, Chen L, Calvert ME, King S, Norheim F, Abad J, Krauss RM, Giacomini KM. Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content. PLoS Biol 2018; 16(4):e2002907.
37 [37] Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek‐Gliszczynski MJ, Zhang L, Consortium IT. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9(3):215–236.
38 [38] Giacomini KM, Galetin A, Huang SM. The international transporter consortium: summarizing advances in the role of transporters in drug development. Clin Pharmacol Ther 2018; 104(5):766–771.
39 [39] Chu X, Chan GH, Evers R. Identification of endogenous biomarkers to predict the propensity of drug candidates to cause hepatic or renal transporter‐mediated drug‐drug interactions. J Pharm Sci 2017; 106(9):2357–2367.
40 [40] Wright SH. Molecular and cellular physiology of organic cation transporter 2. Am J Physiol Renal Physiol 2019; 317(6):F1669–F1679.
41 [41] Urakami Y, Okuda M, Saito H, Inui K. Hormonal regulation of organic cation transporter OCT2 expression in rat kidney. FEBS Lett 2000; 473(2):173–176.
42 [42] Jonker JW, Wagenaar E, Van Eijl S, Schinkel AH. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 2003; 23(21):7902–7908.
43 [43] Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstädt H, Lanvers‐Kaminsky C, Am Zehnhoff‐Dinnesen A, Schinkel AH, Koepsell H, Jürgens H, Schlatter E. Organic cation transporter 2 mediates cisplatin‐induced oto‐ and nephrotoxicity and is a target for protective interventions. Am J Pathol 2010; 176(3):1169–1180.
44 [44] Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, Deyoung J, Taylor T, Clark AG, Herskowitz I, Giacomini KM, Investigators POMT. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 2002; 12(5):395–405.
45 [45] Fujita T, Urban TJ, Leabman MK, Fujita K, Giacomini KM. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 2006; 95(1):25–36.
46 [46] Zwart R, Verhaagh S, Buitelaar M, Popp‐Snijders C, Barlow DP. Impaired activity of the extraneuronal monoamine transporter system known as uptake‐2 in Orct3/Slc22a3‐deficient mice. Mol Cell Biol 2001; 21(13):4188–4196.
47 [47] Vollmar J, Lautem A, Closs E, Schuppan D, Kim YO, Grimm D, Marquardt JU, Fuchs P, Straub BK, Schad A, Gründemann D, Schattenberg JM, Gehrke N, Wörns MA, Baumgart J, Galle PR, Zimmermann T. Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis. Oncotarget 2017; 8(70):115667–115680.
48 [48] Vialou V, Balasse L, Callebert J, Launay JM, Giros B, Gautron S. Altered aminergic neurotransmission in the brain of organic cation transporter 3‐deficient mice. J Neurochem 2008; 106(3):1471–1482.
49 [49] Wultsch T, Grimberg G, Schmitt A, Painsipp E, Wetzstein H, Breitenkamp AF, Gründemann D, Schömig E, Lesch KP, Gerlach M, Reif A. Decreased anxiety in mice lacking the organic cation transporter 3. J Neural Transm (Vienna) 2009; 116(6):689–697.
50 [50] Eeles RA, Kote‐Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern‐Jones AT, Hall AL, O’Brien LT, Gehr‐Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF, Collaborators UGPCS, Oncology BAOUSSO, Collaborators UPS. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40(3):316–321.
51 [51] Cui R, Okada Y, Jang SG, Ku JL, Park JG, Kamatani Y, Hosono N, Tsunoda T, Kumar V, Tanikawa C, Kamatani N, Yamada R, Kubo M, Nakamura Y, Matsuda K. Common variant in 6q26‐q27 is associated with distal colon cancer in an Asian population. Gut 2011; 60(6):799–805.
52 [52] Lazar A, Walitza S, Jetter A, Gerlach M, Warnke A, Herpertz‐Dahlmann B, Gründemann D, Grimberg G, Schulz E, Remschmidt H, Wewetzer C, Schömig E. Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive‐compulsive disorder. Int J Neuropsychopharmacol 2008; 11(1):35–48.
53 [53] Eudy JD, Spiegelstein O, Barber RC, Wlodarczyk BJ, Talbot J, Finnell RH. Identification and characterization of the human and mouse SLC19A3 gene: a novel member of the reduced folate family of micronutrient transporter genes. Mol Genet Metab 2000; 71(4):581–590.
54 [54] Swier LJ, Monjas L, Guskov A, de Voogd AR, Erkens GB, Slotboom DJ, Hirsch AK. Structure‐based design of potent small‐molecule binders to the S‐component of the ECF transporter for thiamine. Chembiochem 2015; 16(5):819–826.
55 [55] Liang X, Chien HC, Yee SW, Giacomini MM, Chen EC, Piao M, Hao J, Twelves J, Lepist EI, Ray AS, Giacomini KM. Metformin is a substrate and inhibitor of the human thiamine transporter, THTR‐2 (SLC19A3). Mol Pharm 2015; 12(12):4301–4310.
56 [56]
